StockData
Arbutus Biopharma Corp logo

Arbutus Biopharma Corp (ABUS) stock

ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 12/3082% below fair value
$3.88+0.06 (+1.57%)

Close on Nov 11, 2026Market cap $767.65MP/E 3.5Yield –

Earnings

Arbutus Biopharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 22, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$300.00K
-40.0% on a year earlier
EPS, Q3 FY2026
$0.30
-$0.04 a year earlier
Latest guidance
Issued
Mar 27, 2025 · 1 item

Quarterly results

Revenue and earnings per share from each of Arbutus Biopharma's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 22, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 10, 2026before the open$300.00K-40.0%$0.30Release
Q2 FY2026ended Jun 30, 2026Aug 12, 2026before the open$1.00M-90.7%-$0.03Release
Q1 FY2026ended Mar 31, 2026May 13, 2026before the open$179.10M+9850.0%$0.87Release
Q4 FY2025ended Dec 31, 2025Mar 23, 2026before the open–––Release
Q3 FY2025ended Sep 30, 2025Nov 13, 2025before the open$500.00K-61.5%-$0.04Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025before the open$10.70M+529.4%$0.01Release
Q1 FY2025ended Mar 31, 2025May 14, 2025before the open$1.80M+20.0%-$0.13Release
Q4 FY2024ended Dec 31, 2024Mar 27, 2025before the open–––Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024before the open$1.30M-72.3%-$0.10Release
Q2 FY2024ended Jun 30, 2024Aug 1, 2024before the open$1.70M-63.8%-$0.11Release
Q1 FY2024ended Mar 31, 2024May 2, 2024before the open$1.50M-77.6%-$0.10Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Arbutus Biopharma guided for has been reported

Guidance history

Every forecast Arbutus Biopharma put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Mar 27, 2025one-time restructuring chargeQ1 FY2025$11.00M – $13.00MNew
Jan 13, 2025Net cash burnFY2025$47.00M – $50.00MNew
Nov 6, 2024cash burnFY2024$63.00M – $67.00MReaffirmed
Aug 1, 2024cash burnFY2024$63.00M – $67.00MReaffirmed
May 2, 2024net cash burnFY2024$63.00M – $67.00MReaffirmed
Feb 29, 2024net cash burnFY2024$63.00M – $67.00MNew
Nov 7, 2023net cash burnFY2023$90.00M – $95.00MReaffirmed
Aug 3, 2023net cash burnFY2023$90.00M – $95.00MReaffirmed
May 4, 2023cash burnFY2023$90.00M – $95.00MLowered
Mar 2, 2023net cash burnFY2023$95.00M – $100.00MNew
Nov 9, 2022net cash burnFY2022$90.00M – $95.00MReaffirmed
Aug 4, 2022net cash burnFY2022$90.00M – $95.00MReaffirmed
May 5, 2022net cash burnFY2022$90.00M – $95.00MReaffirmed
Mar 3, 2022net cash burnFY2022$90.00M – $95.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Arbutus Biopharma filed with the SEC as exhibits to Form 8-K or 6-K

  1. © 2026 ARBUTUS BIOPHARMA, INC 1 WWW.ARBUTUSBIO.COM © 2026 ARBUTUS BIOPHARMA, INC CORPORATE PRESENTATION Q4 2026 NASDAQ: ABUS
    News
  2. Arbutus Reports Third Quarter 2026 Financial Results and Provides Corporate Update
    Results
  3. Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor
    News
  4. Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
    News
  5. Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update
    Results
  6. 8-K exhibit EX-99.1
    News
  7. Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
    Results
  8. Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
    News
  9. Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
    Results
  10. Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
    News
  11. 8-K exhibit EX-99.1
    News
  12. 8-K exhibit EX-99.1
    News
  13. For investor audiences only 19 We believe that both the Moderna COVID - 19 vaccine (SPIKEVAX) and Pfizer/BioNTech
    News
  14. Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    Results
  15. ©2025 ARBUTUS BIOPHARMA, INC. Imdusiran RNAi Therapeutic | 8
    Results

See a number that looks wrong?